1-(2-甲基环戊基)乙酮 | 1601-00-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2-甲基环戊基)乙酮
• 英文名称: methyl 2-methylcyclopentyl ketone
• 英文别名: 1-(2-methylcyclopentyl)ethanone；1-acetyl-2-methylcyclopentane；1-(2-methyl-cyclopentyl)-ethanone；Methyl-(2-methyl-cyclopentyl)-keton；1-(2-Methyl-cyclopentyl)-aethanon；Methyl-(2-methylcyclopentyl)-keton；trans-1-Acetyl-2-methylcyclopentane
• CAS: 1601-00-9
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: SIXBTZFYFSHXJI-UHFFFAOYSA-N

物化性质

• 沸点：
  170.5°C (estimate)
• 密度：
  0.9222

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914299000

反应信息

• 作为反应物：
  描述：

  1-(2-甲基环戊基)乙酮 生成 (+/-)-1.2c-dimethyl-cyclopentane-carboxylic acid-(1r)-amide
  参考文献：
  名称：

  La cyclisation thermique des cetones εζ-ethyleniques

  摘要：

  DOI：

  10.1016/s0040-4039(01)89201-7
• 作为产物：
  描述：

  2-甲基四氢呋喃 在 盐酸 、 三氯化铝 、 sodium ethanolate 、 三溴化磷 作用下， 以 甲醇 、 乙醇 、 Petroleum ether 为溶剂， 生成 1-(2-甲基环戊基)乙酮
  参考文献：
  名称：

  Solvents of low nucleophilicity. XII. Triple-bond participation in the acetolysis, formolysis, and trifluoroacetolysis of 6-heptyn-2-yl tosylate and 6-octyn-2-yl tosylate

  摘要：

  DOI：

  10.1021/ja01044a035

文献信息

• COMPOUNDS USEFUL AS MODULATORS OF TRPM8
  申请人：SENOMYX, INC.

  公开号：US20150376136A1

  公开（公告）日：2015-12-31

  The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formulae (Ia), (Ib) and (Ic), and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations.

  本发明包括作为TRPM8调节剂有用的化合物，例如式(Ia)、(Ib)和(Ic)的化合物，以及其亚属和种类；含有这些化合物的个人产品；以及利用这些化合物和个人产品，特别是利用增加或诱导化学感觉，如凉爽或冷感觉。
• Electrochemical Coupling of Biomass-Derived Acids: New C₈Platforms for Renewable Polymers and Fuels
  作者：Linglin Wu、Mark Mascal、Thomas J. Farmer、Sacha Pérocheau Arnaud、Maria-Angelica Wong Chang

  DOI：10.1002/cssc.201601271

  日期：2017.1.10

  biomass-derived carbonyl compounds is an alternative to condensation chemistry for supplying products with chain length >C6 for biofuels and renewable materials production. Kolbe coupling of biomass-derived levulinic acid is used to obtain 2,7-octanedione, a new platform molecule only two low process-intensity steps removed from raw biomass. Hydrogenation to 2,7-octanediol provides a chiral secondary diol

  源自生物质的羰基化合物的电解是缩合化学的替代方法，可提供链长> C6的产品用于生物燃料和可再生材料的生​​产。生物质衍生的乙酰丙酸的Kolbe偶联用于获得2,7-辛二酮，这是一种新的平台分子，仅从原始生物质中去除了两个低过程强度步骤。氢化成2,7-辛二醇提供了手性仲二醇，这在高分子化学中是未知的，而分子内醇醛缩合然后氢化则得到了适合用作高辛烷值，纤维素汽油的支链环烷烃。衣康酸衍生的甲基琥珀酸单酯的类似电解产生手性2,5-二甲基己二酸二酯，由于缺乏可利用性而另一种未被充分利用的单体。
• Methods and compositions of novel triazine compounds
  申请人：Timmer T. Richard

  公开号：US20070117795A1

  公开（公告）日：2007-05-24

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及治疗由炎症反应引起的病理生理状况的方法和组合物。特别是，本发明涉及抑制或阻断糖基化蛋白质诱导内皮细胞信号相关炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。特别是，本发明涉及通过调节HSPGs（如Perlecan）抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物治疗以平滑肌增殖为特征的血管闭塞性疾病，如再狭窄和动脉粥样硬化。
• Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239838A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  提供了包括公式I或其药学上可接受的盐或组合物的补体因子D抑制剂的化合物、使用方法和制备方法。本文所描述的抑制剂靶向因子D并在替代补体途径的早期和关键点上抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。本文所述的因子D抑制剂能够减少补体过度激活，该过度激活已与某些自身免疫性、炎症性和神经退行性疾病以及缺血再灌注损伤和癌症有关。
• Amide compounds for treatment of complement mediated disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US10005802B2

  公开（公告）日：2018-06-26

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R12 or R13 on the A group is an amide substituent (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade in the alternative complement pathway. The inhibitors of factor D described herein reduce the excessive activation of complement.

  提供了包含式 I 或其药学上可接受的盐或组合物的化合物、使用方法和补体因子 D 抑制剂的制造工艺，其中 A 基上的 R12 或 R13 是酰胺取代基 (R32)。 本文所述的抑制剂以因子 D 为靶点，抑制或调节替代补体途径中的补体级联。 本文所述的因子 D 抑制剂可减少补体的过度激活。